ZOP-1 significantly improved the shortening and thickening of the colon, changed the index of immune organs, inhibited the production of inflammatory factors in mice with ulcerative colitis, changed the intestinal flora of mice, increased the content of short-chain fatty acids (SCFAs) in the intestine, and controlled the TLR4/NF-κB/MAPK signaling pathway, thus preventing and treating DSS-induced ulcerative colitis in mice. Here, TLR4 is linked to ulcerative colitis.